Developing improved tools to manipulate and study the activity of genes in living cells

Founded by Anastasia Khvorova, PhD and Alexey Wolfson, PhD in 2007 to develop new nucleic based technologies for therapeutic and research use. Advirna has developed a proprietary self-deliverable RNAi technology and reduced it to practice in collaboration with RXi Pharmaceuticals. Advirna's platform provides researchers with better tools to study and manipulate activity of genes in living cells.

Advirna is a private biotechnology company developing innovative solutions for efficient delivery of polynucleotides in vivo. Advirna’s self-deliverable RNAi is based on the recent breakthrough in biology known as RNA interference (RNAi). This discovery opened a possibility to specifically regulate activity of genes inside a living cell. 

Alexey Wolfson, PhD, MBA Founder & CEO

Alexey Wolfson, PhD, MBA

Founder & CEO

Taisia Shmushkovich, MD, PhD Scientist

Taisia Shmushkovich, MD, PhD

Scientist

Kathryn Monopoli, MS Associate Scientist

Kathryn Monopoli, MS

Associate Scientist

Anastasia Khvorova, PhD Scientific Advisor

Anastasia Khvorova, PhD

Scientific Advisor

Greg Hannon, PhD Scientific Advisor

Greg Hannon, PhD

Scientific Advisor

Craig Mello, PhD Scientific Advisor

Craig Mello, PhD

Scientific Advisor

Tod Woolf, PhD Scientific Advisor

Tod Woolf, PhD

Scientific Advisor